Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in ALK-negative High pALK NSCLC
NCT05792644Completed
- Sponsor
- Harbin Medical University
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Harbin Medical University. Primary endpoint: Clinical efficacy at 6 months. Started Jan 2018; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05792644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792644.